Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Novartis Ag (NVSEF) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to 0.42.

  • Novartis Ag's Equity Ratio fell 278.38% to 0.42 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.42, marking a year-over-year decrease of 278.38%. This contributed to the annual value of 0.42 for FY2025, which is 278.38% down from last year.
  • Novartis Ag's Equity Ratio amounted to 0.42 in Q4 2025, which was down 278.38% from 0.01 recorded in Q1 2025.
  • Over the past 5 years, Novartis Ag's Equity Ratio peaked at 0.51 during Q4 2021, and registered a low of 0.01 during Q1 2022.
  • For the 5-year period, Novartis Ag's Equity Ratio averaged around 0.22, with its median value being 0.01 (2025).
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 1504.25% in 2021, then tumbled by 773.7% in 2024.
  • Novartis Ag's Equity Ratio (Quarter) stood at 0.51 in 2021, then dropped by 1.69% to 0.51 in 2022, then dropped by 7.55% to 0.47 in 2023, then decreased by 7.74% to 0.43 in 2024, then dropped by 2.78% to 0.42 in 2025.
  • Its Equity Ratio stands at 0.42 for Q4 2025, versus 0.01 for Q1 2025 and 0.43 for Q4 2024.